Consumer Assessment of Tobacco Flavor and Odor

April 16, 2024 updated by: Roswell Park Cancer Institute
This trial studies consumer assessments of tobacco flavor and odor. This study will compare the ability of expert and consumer panels to identify and characterize flavors, determine threshold detection levels for individual and mixed flavors, and identify the dominant flavor of mixtures.

Study Overview

Detailed Description

PRIMARY OBJECTIVE:

I. Develop consumer (untrained) sensory panels to identify and assess characterizing flavors in electronic (e)-liquids.

OUTLINE:

Non-user panelists smell and user panelists puff flavored e-liquids and answer questions about the products.

Study Type

Observational

Enrollment (Estimated)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • Buffalo, New York, United States, 14263
        • Recruiting
        • Roswell Park Cancer Institute
        • Contact:
        • Principal Investigator:
          • Richard J. O'Connor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Current daily vapers and nonusers in the greater Buffalo and Rochester areas

Description

Inclusion Criteria:

  • CONSUMER USER: Current daily vapers of products containing nicotine
  • CONSUMER USER: No concurrent use of other tobacco products
  • CONSUMER USER: General good health
  • CONSUMER USER: No allergies
  • CONSUMER USER: No self-reported taste or smell deficits
  • CONSUMER USER: Not pregnant or lactating
  • CONSUMER USER: No medications known to interfere with taste/smell
  • CONSUMER USER: Passing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
  • CONSUMER USER: No positive diagnosis of COVID-19 within 30 days
  • CONSUMER NONUSER: No use of tobacco or nicotine products in the last year
  • CONSUMER NONUSER: General good health
  • CONSUMER NONUSER: No allergies
  • CONSUMER NONUSER: No self-reported taste or smell deficits
  • CONSUMER NONUSER: Not pregnant or lactating
  • CONSUMER NONUSER: No medications known to interfere with taste/smell
  • CONSUMER NONUSER: Passing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
  • CONSUMER NONUSER: No positive diagnosis of COVID-19 within 30 days

Exclusion Criteria:

  • CONSUMER USER: Outside age range
  • CONSUMER USER: Not current daily vapers
  • CONSUMER USER: Concurrent use of other tobacco products
  • CONSUMER USER: Fair or poor general health
  • CONSUMER USER: Allergies
  • CONSUMER USER: Self-reported taste or smell deficits
  • CONSUMER USER: Pregnant or lactating
  • CONSUMER USER: Medications known to interfere with taste/smell
  • CONSUMER USER: Failing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
  • CONSUMER USER: Positive diagnosis of COVID-19 within 30 days
  • CONSUMER NONUSER: Outside age range
  • CONSUMER NONUSER: Use of tobacco or nicotine products in the last year
  • CONSUMER NONUSER: Fair or poor general health
  • CONSUMER NONUSER: Allergies
  • CONSUMER NONUSER: Self-reported taste or smell deficits
  • CONSUMER NONUSER: Pregnant or lactating
  • CONSUMER NONUSER: Medications known to interfere with taste/smell
  • CONSUMER NONUSER: Failing scores on the Brief Smell Identification Test (B-SIT), phenylthiocarbamine (PTC) and 6-n-propylthiouracil (PROP) smell and taste tests
  • CONSUMER NONUSER: Positive diagnosis of COVID-19 within 30 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Observational (smell or puff e-liquids)
All panel participants smell and user panelists puff flavored e-liquids and answer questions about the products.
Ancillary studies
Smell or puff e-liquids
Other Names:
  • Behavior Conditioning Therapy
  • Behavior or Life Style Modifications
  • Behavior Therapy
  • Behavioral Interventions
  • Behavioral Modification
  • Behavioral Therapy
  • Behavioral Treatment
  • Behavioral Treatments
  • behavior modification

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Flavor identification and evaluation
Time Frame: Up to 12 months
Subjects will be asked to identify various concentrations of flavored e-liquids
Up to 12 months
Specific flavor detection thresholds
Time Frame: Up to 12 months
Subjects will rate intensity of odors of e liquids
Up to 12 months
Flavor combination thresholds
Time Frame: Up to 12 months
Subjects will rate a combination of two e-liquids combined
Up to 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Richard J O'Connor, Roswell Park Cancer Institute

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 3, 2023

Primary Completion (Estimated)

October 3, 2027

Study Completion (Estimated)

October 3, 2027

Study Registration Dates

First Submitted

April 13, 2020

First Submitted That Met QC Criteria

April 20, 2020

First Posted (Actual)

April 24, 2020

Study Record Updates

Last Update Posted (Actual)

April 17, 2024

Last Update Submitted That Met QC Criteria

April 16, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • I 80518 (Other Identifier: Roswell Park Cancer Institute)
  • U54CA228110 (U.S. NIH Grant/Contract)
  • NCI-2019-06320 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Subject

Clinical Trials on Questionnaire Administration

3
Subscribe